Table 2 Outcomes between two treatment arms in the intention-to-treat population
Total (N = 406) | Placebo (n = 194) | Tirofiban (n = 212) | P-value | |
|---|---|---|---|---|
Efficacy outcomes | ||||
3-month mRS score | 3(1–4) | 3(1–4) | 3(1–4) | 0.941 |
3-month mRS score 0–1, n (%) | 149(36.7) | 69(35.6) | 80(37.7) | 0.681 |
3-month mRS score 0–2, n (%) | 202(49.8) | 96(49.5) | 106(50) | 0.921 |
3-month mRS score 0–3, n (%) | 251(61.8) | 121(62.4) | 130(61.3) | 0.839 |
NIHSS 24 h minus baseline | − 2(− 6 to 2) | − 2(− 6 to 2) | − 2(− 6 to 2) | 0.825 |
NIHSS 7d minus baseline | − 5(− 10 to 1) | − 5(− 10 to 1) | − 5(− 10 to 2) | 0.358 |
Reperfusion at 48 h, n (%) | 295(96.4) | 144(97.3) | 151(95.6) | 0.417 |
3-month EQ5D5L | 0.7(0.2–1.0) | 0.7(0.2–0.9) | 0.7(0.2–1.0) | 0.863 |
Safety outcomes | ||||
sICH, n (%) | 33(8.1) | 7(3.6) | 26(12.3) | 0.002 |
Any ICH, n (%) | 148(36.5) | 62(32.1) | 86(40.6) | 0.078 |
3-month death, n (%) | 76(18.7) | 31(16) | 45(21.2) | 0.176 |